Ann: Notice of Annual General Meeting/Proxy Form, page-30

COMPANY NAME:

• I am pleased to see the name change and fresh and clear focus
• Put behind the history, but not throw it away (particularly the safety data and data relating to other treatment areas of prospect)
• Separate from PharmAust Manufacturing (and I also fully expect the logo needs a change! )
• I am sure the board would have researched the name for the relevant markets / jurisdictions.

REM etc
THought the rem was not outlandish

LTI
I thought they are just targets and not so "Long Term" - such as first patient on 2/3 trial. Orphan Drug status in EU could be short to medium term, not leaving - ok - long term (unless sold)

FORMER BOARD
The company has to close it out and so I am going to support the proposed exit strategy for their outstanding package.

Will have a good read of it all tonight or tomorrow but my position is - it all looks reasonable and time to give the new board & company staff a chance to show they can deliver.


adreamer